FDA Seeks Specificity Over Sensitivity To ID Potentially Proarrhythmic Drugs
Executive Summary
The agency is looking at preclinical measurement of a drug’s effect on multiple ion channels, in silico modeling and stem cell assays as a possible alternative to “thorough” QT tests to assess the therapy’s impact on heart rhythm.